IRIS
MARTINI, ALBERTO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 39.574
Totale 39.574
Salva come PNG Salva come JPEG
Nazione #
IT - Italia 39.574
Totale 39.574
Salva come PNG Salva come JPEG
Città #
Genova 32.896
Rapallo 4.085
Genoa 2.528
Bordighera 65
Totale 39.574
Salva come PNG Salva come JPEG
Nome #
Relationship between damage accrual, disease flares and cumulative drug therapies in juvenile-onset systemic lupus erythematosus. 237
Malattia di Menetrier e gastropatia ipertrofica proteino-disperdente transitoria del bambino: due entità cliniche distinte? 183
Novel automated system for Magnetic Resonance Imaging quantification of the inflamed synovial membrane volume in patients with juvenile idiopathic arthritis. 171
HRCT and pulmonary function tests in monitoring of lung involvement in juvenile systemic sclerosis. 158
A longitudinal printo study on growth and puberty in juvenile systemic lupus erythematosus. 154
Parent and child acceptable symptom state in juvenile idiopathic arthritis. 151
Candidate Genes in Patients with Autoinflammatory Syndrome Resembling Tumor Necrosis Factor Receptor-associated Periodic Syndrome Without Mutations in the TNFRSF1A Gene 150
Abatacept in children with juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled withdrawal trial. 148
Assessment of damage in juvenile-onset systemic lupus erythematosus: a multicenter cohort study. 145
Differentiating PFAPA syndrome from monogenic periodic fevers. 139
A Meta-Analysis to Estimate the Placebo Effect in Randomized Controlled Trials in Juvenile Idiopathic Arthritis 138
ADA2 deficiency (DADA2) as an unrecognised cause of early onset polyarteritis nodosa and stroke: a multicentre national study 138

Dynamic Contrast-Enhanced Magnetic Resonance Imaging in Assessment of Disease Activity in Patients with Juvenile Idiopathic Arthritis 137
Agreement among musculoskeletal pediatric specialists in the assessment of radiographic joint damage in juvenile idiopathic arthritis. 137
Self epitopes shared between human skeletal myosin and Streptococcus pyogenes M5 protein are targets of immune responses in active juvenile dermatomyositis. 136
A proposal for a pediatric version of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index based on the analysis of 1,015 patients with juvenile-onset systemic lupus erythematosus. 134
Whole-body MRI in the assessment of disease activity in juvenile dermatomyositis 131
Achievement of a state of inactive disease at least once in the first 5 years predicts better outcome of patients with polyarticular juvenile idiopathic arthritis. 130
Phenotypic and functional characterization of switch memory B cells from patients with oligoarticular juvenile idiopathic arthritis 129
Prevalence of anticardiolipin antibodies in juvenile chronic arthritis. 129
Marked and sustained improvement 2 years after autologous stem cell transplantation in a girl with systemic sclerosis. 129
In vivo neutralization of human IL-6 (hIL-6) achieved by immunization of hIL-6 transgenic mice with a hIL-6 receptor antagonist 128
The EULAR/PRINTO/PRES criteria for Henoch-Schönlein purpura, childhood polyarteritis nodosa, childhood Wegener granulomatosis, and childhood Takayasu arteritis: ankara 2008. part ii: final classification criteria. 128
Preliminary core sets of measures for disease activity and damage assessment in juvenile systemic lupus erythematosus and juvenile dermatomyositis. 127
The pattern of response to anti-interleukin-1 treatment distinguishes two subsets of patients with systemic-onset juvenile idiopathic arthritis. 127
Health-related quality of life in juvenile-onset systemic lupus erythematosus and its relationship to disease activity and damage. 126
Antiphospholipid antibody syndrome in pediatric patients. 126
Phenotypic and functional characterisation of CCR7+ and CCR7- CD4+ memory T cells homing to the joints in juvenile idiopathic arthritis. 126
Interferon-γ-dependent inhibition of B cell activation by bone marrow-derived mesenchymal stem cells in a murine model of systemic lupus erythematosus. 126
Expert consensus on dynamics of laboratory tests for diagnosis of macrophage activation syndrome complicating systemic juvenile idiopathic arthritis 125
EULAR-PReS points to consider for the use of imaging in the diagnosis and management of juvenile idiopathic arthritis in clinical practice 125
Therapeutic approaches in the treatment of juvenile dermatomyositis in patients with recent-onset disease and in those experiencing disease flare: an international multicenter PRINTO study 124
Aortic valve regurgitation as the presenting sign of Takayasu arteritis. 123
Hypocomplementemic urticarial vasculitis syndrome with severe systemic manifestations 123
Neurological disorders, other than stroke, associated with antiphospholipid antibodies in childhood. 123
High prevalence of antiphospholipid antibodies in children with idiopatic cerebral ischemia 122
Recurrent pericarditis in Myhre syndrome. 122
Intra-articular corticosteroids versus intra-articular corticosteroids plus methotrexate in oligoarticular juvenile idiopathic arthritis: a multicentre, prospective, randomised, open-label trial 122
CD70 deficiency due to a novel mutation in a patient with severe chronic EBV infection presenting as a periodic fever 122
Tolerance and auto-immunity: 50 years after burnet. 121
A randomized, placebo-controlled trial of infliximab plus methotrexate for the treatment of polyarticular-course juvenile rheumatoid arthritis 121
Paediatric-onset systemic lupus erythematosus. 121
Radiologic progression in patients with juvenile chronic arthritis treated with methotrexate. 120
Disease status, reasons for discontinuation and adverse events in 1038 Italian children with juvenile idiopathic arthritis treated with etanercept 120
Clinical assessment in juvenile dermatomyositis. 119
Adapted versions of the Sharp-van Der Heijde score are reliable and valid for assessment of radiographic progression in juvenile idiopathic arthritis 119
Dissecting the heterogeneity of macrophage activation syndrome complicating systemic juvenile idiopathic arthritis 119
Efficacy and safety of tocilizumab in patients with polyarticular-course juvenile idiopathic arthritis: results from a phase 3, randomised, double-blind withdrawal trial. 119
Outcome and predicting factors of single and multiple intra-articular corticosteroid injections in children with juvenile idiopathic arthritis 118
Discordance between proxy-reported and observed assessment of functional ability of children with juvenile idiopathic arthritis. 118
Relative responsiveness of condition specific and generic health status measures in juvenile idiopathic arthritis. 118
The role of imaging in juvenile idiopathic arthritis 118
Performing trials in children with rheumatic diseases: Comment on the editorial by Lehman 117
2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: initiation and safety monitoring of therapeutic agents for the treatment of arthritis and systemic features 117
Diagnostic potential of hepcidin testing in pediatrics. 117
Discordance between physician’s and parent’s global assessments in juvenile idiopathic arthritis 117
Prednisone versus prednisone plus ciclosporin versus prednisone plus methotrexate in new-onset juvenile dermatomyositis: A randomised trial 117
2016 Classification criteria for macrophage activation syndrome complicating systemic juvenile idiopathic arthritis: A European league against Rheumatism/American college of Rheumatology/Paediatric rheumatology international trials organisation collaborative initiative 117
A positive family history of psoriasis does not affect the clinical expression and course of juvenile idiopathic arthritis patients with oligoarthritis. 116
Level of agreement between children, parents and physicians in rating pain intensity in juvenile idiopathic arthritis. 116
Evaluation of response to methotrexate by a functional index in juvenile chronic arthritis. 116
Remission, minimal disease activity, and acceptable symptom state in juvenile idiopathic arthritis: Defining criteria based on the juvenile arthritis disease activity score 116
Preliminary definition of improvement in juvenile arthritis. 115
Evaluation of 21-Numbered Circle and 10-Centimeter Horizontal Line Visual Analog Scales for Physician and Parent Subjective Ratings in Juvenile Idiopathic Arthritis 115
Bone marrow-derived mesenchymal stem cells induce both polyclonal expansion and differentiation of B cells isolated from healthy donors and systemic lupus erythematosus patients 115
Variation of serum IgG subclass concentrations with disease activity in juvenile chronic arthritis. 115
Advances from clinical trials in juvenile idiopathic arthritis. 115
Use of the Sharp and Larsen scoring methods in the assessment of radiographic progression in juvenile idiopathic arthritis. 115
Development and Initial Validation of the Macrophage Activation Syndrome/Primary Hemophagocytic Lymphohistiocytosis Score, a Diagnostic Tool that Differentiates Primary Hemophagocytic Lymphohistiocytosis from Macrophage Activation Syndrome 114
Impact of involvement of individual joint groups on subdimensions of functional ability scales in juvenile idiopathic arthritis 113
Development and testing of reduced joint counts in juvenile idiopathic arthritis. 113
Cytokines in juvenile rheumatoid arthritis. 113
Antiphospholipid antibody associated thrombosis in juvenile chronic arthritis. 113
TCR repertoire sequencing identifies synovial Treg cell clonotypes in the bloodstream during active inflammation in human arthritis 113
Phagocyte-specific S100 proteins and high-sensitivity C reactive protein as biomarkers for a risk-adapted treatment to maintain remission in juvenile idiopathic arthritis: a comparative study. 113
Cross-cultural adaptation and psychometric evaluation of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) in 54 languages across 52 countries: review of the general methodology 113
Delineating the application of ultrasound in detecting synovial abnormalities of subtalar joint in juvenile idiopathic arthritis 113
Development and initial validation of composite parent and child centered disease assessment indices for juvenile idiopathic arthritis. 113
Chronic recurrent multifocal osteomyelitis with unusual features. 112
Factors associated with response to methotrexate in systemic-onset juvenile chronic arthritis. 112
A phase II, multicenter, open-label study evaluating dosing and preliminary safety and efficacy of canakinumab in systemic juvenile idiopathic arthritis with active systemic features. 112
Next-generation sequencing and its initial applications for molecular diagnosis of systemic auto-inflammatory diseases 112
The Croatian version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) 112
Autologous stem cell transplantation in the treatment of systemic sclerosis: report from the EBMT/EULAR Registry. 112
Antiphospholipid antibody syndrome as a cause of venous thrombosis in childhood. 111
Treatment of autoinflammatory diseases: results from the Eurofever Registry and a literature review. 111
Lupus nephritis in children. 111
The Italian version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) 111
A randomized, double-blind, placebo-controlled trial of paracetamol and ketoprofren lysine salt for pain control in children with pharyngotonsillitis cared by family pediatricians 111
Advances in biomarkers for paediatric rheumatic diseases 111
Patients with antinuclear antibody-positive juvenile idiopathic arthritis constitute a homogeneous subgroup irrespective of the course of joint disease 110
The phenotype of TNF receptor-associated autoinflammatory syndrome (TRAPS) at presentation: a series of 158 cases from the Eurofever/EUROTRAPS international registry. 110
Multi-antibody composition in lupus nephritis: Isotype and antigen specificity make the difference 110
Development and testing of a hybrid measure of muscle strength in juvenile dermatomyositis for use in routine care 110
Macrophage activation syndrome 109
Performance of current guidelines for diagnosis of macrophage activation syndrome complicating systemic juvenile idiopathic arthritis. 109
What is juvenile psoriatic arthritis? Comment on the article by Stoll et al. 109
A New Approach to Clinical Care of Juvenile Idiopathic Arthritis: The Juvenile Arthritis Multidimensional Assessment Report 109
Development and validation of a composite disease activity score for juvenile idiopathic arthritis 109
Two randomized trials of canakinumab in systemic juvenile idiopathic arthritis. 109
Totale 12.319
Salva come PNG Salva come JPEG
Categoria #
all - tutte 106.027
article - articoli 104.900
book - libri 0
conference - conferenze 143
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 984
Totale 212.054
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/20191.682 0 0 0 0 0 0 0 0 0 0 926 756
2019/202012.315 565 343 492 735 1.009 1.149 2.339 822 1.042 2.083 1.287 449
2020/20213.183 165 304 272 399 167 285 140 277 298 367 221 288
2021/20225.630 171 429 630 450 325 241 443 1.293 206 456 331 655
2022/20234.959 552 245 44 421 850 978 23 467 921 33 347 78
2023/20241.722 147 374 45 211 197 347 118 134 96 53 0 0
Totale 40.146